Marinus Pharmaceuticals

Company profile

About

Marinus Pharmaceuticals (NASDAQ:MRNS) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of epilepsy and other neuropsychiatric disorders. The company's portfolio is centered around its lead candidate, ganaxolone, which is being explored across multiple studies for its potential in treating a range of seizure disorders and neuropsychiatric conditions. Marinus is committed to advancing neuroscience and aiming to provide new treatment options for patients with unmet medical needs. Through ongoing research and development projects, Marinus strives to expand its understanding of neurological diseases and harness the power of its technology to improve patient outcomes.

Snapshot

2003Year founded

172Employees

Pennsylvania, United StatesHead office

Loading Map...

Global footprint

Operations

All Locations

United States

Products and/or services of Marinus Pharmaceuticals

Ganaxolone for CDKL5 deficiency disorder, a rare form of epilepsy in children.
Development of ganaxolone for status epilepticus, severe seizures that do not respond to first-line treatments.
Research into ganaxolone for Postpartum Depression, addressing severe mood disorders following childbirth.
Investigation of ganaxolone in Tuberous Sclerosis Complex, aiming to reduce seizure frequency in this genetic disorder.
Exploration of ganaxolone for treatment-resistant depression, targeting individuals unresponsive to standard therapies.
Advancing a proprietary intravenous formulation of ganaxolone for use in hospital settings, enhancing rapid delivery for acute management.